Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity

PURPOSE: The purpose of this study was to report on the axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for threshold retinopathy of prematurity. METHODS: The authors conducted a comparative, consecutive, original study. RESULTS: Twenty-five ey...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chun-Ju, Tsai, Yi-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959583/
https://www.ncbi.nlm.nih.gov/pubmed/27499611
http://dx.doi.org/10.2147/OPTH.S110717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959583/
https://www.ncbi.nlm.nih.gov/pubmed/27499611
http://dx.doi.org/10.2147/OPTH.S110717

Ejemplares similares